₹5,595.50
−3.68%NSE close, 16 Nov 2026
−4.17%
Procter & Gamble Health is a small cap company in the Healthcare sector, listed on NSE under the symbol PGHL. At ₹5,595.50 a share, the market values the whole company at ₹9,288 crore.
In Dec 2024, it reported sales of ₹1,160 crore and a net profit of ₹237 crore, an operating margin of 30.5%. Over the last three years, sales grew 3.2% a year and net profit grew 16.4% a year.
The market values the company at 24.5 times its profit over the last twelve months and 14.11 times its book value; its return on equity is 57.7% and it has almost no borrowings.
Promoters hold 51.82% of the shares. Foreign institutions hold 6.42%, and domestic institutions, mutual funds among them, 12.63%.
Over the past year the share price has fallen 6.7%, and it is 19.8% below its 52-week high.
Companies of a similar size in the same sector include Park Medi World, Viyash Scientific, Yatharth Hospital & Trauma Care Services and Blue Jet Healthcare.
₹ crore. Standalone figures: the company files no consolidated results.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
| Park Medi World | ₹245.03 | ₹10,584 cr | 41.3 | 11.9% | n/a | n/a |
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 |
. Change in Corporate Office address of Registrar and Share Transfer Agent (RTA)
A press release for Unaudited Financial Results for Quarter ended September 30, 2026.
The financial results for the period ended September 30, 2026.
Update on Intimation Regarding Ease of Doing Investment - Special Window for Transfer and Dematerialization
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 | 382 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 | 230 |
| Operating profit | 102 | 67.4 | 48.3 | 114 | 123 | 80.9 | 90.3 | 120 | 110 | 136 | 99.6 | 152 |
| Operating margin | 32.8% | 26.7% | 17.0% | 36.4% | 39.8% | 26.0% | 26.7% | 37.0% | 29.5% | 36.6% | 27.4% | 39.8% |
| Other income | 5.2 | 2.3 | 2.1 | 3.3 | 4.0 | 3.1 | 4.0 | 5.0 | 4.4 | 4.0 | 3.9 | 3.9 |
| Interest | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 |
| Depreciation | 6.9 | 6.8 | 7.2 | 5.8 | 5.6 | 5.4 | 5.4 | 6.1 | 5.9 | 6.2 | 6.0 | 6.1 |
| Profit before tax | 99.7 | 62.7 | 22.8 | 111 | 122 | 78.5 | 88.8 | 119 | 109 | 133 | 129 | 150 |
| Tax | 27.7 | 16.2 | 6.1 | 29.1 | 30.8 | 17.4 | 22.6 | 30.5 | 31.2 | 38.6 | 33.0 | 38.5 |
| Net profit | 72.1 | 46.6 | 16.8 | 82.3 | 90.9 | 61.2 | 66.2 | 88.5 | 77.6 | 94.6 | 96.2 | 112 |
| EPS (₹) | 43.40 | 28.00 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 | 67.18 |
₹ crore, financial years to Dec.
| Line | Dec 2018 | Dec 2019 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|
| Sales | 849 | 927 | 1,055 | 1,171 | 1,237 | 1,160 |
| Expenses | 702 | 723 | 836 | 841 | 924 | 806 |
| Operating profit | 147 | 204 | 219 | 330 | 313 | 353 |
| Operating margin | 17.4% | 22.0% | 20.8% | 28.2% | 25.3% | 30.5% |
| Other income | 24.4 | 47.9 | 13.4 | 13.4 | 21.7 | 11.6 |
| Interest | 0 | 0 | 0.6 | 0.6 | 0.8 | 0.7 |
| Depreciation | 20.4 | 17.2 | 28.3 | 31.6 | 23.5 | 25.3 |
| Profit before tax | 158 | 234 | 204 | 311 | 310 | 319 |
| Tax | 56.2 | 75.6 | 53.7 | 78.2 | 83.8 | 82.1 |
| Net profit | 839 | 159 | 150 | 233 | 227 | 237 |
| EPS (₹) | 505.27 | 95.64 | 90.30 | 140.20 | 136.56 | 142.47 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | Jun 2021 | Jun 2022 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 247 | 170 | 338 | 191 |
| From investing | −32.3 | −25.5 | 1.3 | 31.7 |
| From financing | −387 | −289 | −344 | −77.0 |
| Spent on fixed assets | −52.6 | −37.9 | −15.5 | −9.7 |
| Free cash flow | 195 | 132 | 322 | 181 |
Margins, returns, debt, tax and cash.
| Line | Dec 2018 | Dec 2019 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|
| Net margin | 98.8% | 17.1% | 14.2% | 19.9% | 18.3% | 20.4% |
| Operating margin | 17.4% | 22.0% | 20.8% | 28.2% | 25.3% | 30.5% |
| Return on equity | – | – | – | 31.7% | 28.1% | 38.8% |
| Return on capital employed | – | – | – | 42.4% | 38.6% | 52.3% |
| Return on assets | – | – | – | 21.6% | 21.0% | 27.2% |
| Debt to equity | – | – | – | 0.00 | 0.00 | 0.00 |
| Interest coverage | – | – | 324.10 | 566.50 | 414.90 | 491.20 |
| Debt to assets | – | – | – | 0.00 | 0.00 | 0.00 |
| Current ratio | – | – | – | 2.71 | 3.35 | 2.78 |
| Quick ratio | – | – | – | – | 2.79 | 2.24 |
| Cash ratio | – | – | – | 1.41 | 1.82 | 1.21 |
| Asset turnover | – | – | – | 1.08 | 1.15 | 1.33 |
| Fixed asset turnover | – | – | – | 10.66 | 9.50 | 10.53 |
| Inventory turnover | – | – | – | – | 2.90 | 2.70 |
| Receivables turnover | – | – | – | – | 9.10 | 8.90 |
| Gross margin | – | – | – | – | 70.0% | 72.7% |
| Effective tax rate | 35.6% | 32.3% | 26.4% | 25.2% | 27.0% | 25.8% |
| 12.4% |
| +127.10% |
| −8.67% |
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
|---|
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
|---|
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
|---|
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
|---|
This is in reference to our letter dated May 26, 2026, regarding re-appointment of Mr. S.Madhavan as Independent Director of the Company, for a period of five years, with effect fromNovember 15, 2026, subject to the approval of the shareholders of the Company. We are…
A copy Srutinizers report of Annual General Meeting held on September 03, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 03, 2026
The Record date has been revised to 27-Aug-2026 for the purpose of DI.
Press Release on the unaudited Financial Results for the quarter ended June 30, 2026
The financial results for the quarter ended June 30, 2026.
Revision in date of Company s Annual General Meeting for the Financial Year 2025-26 and Record date for the purpose of AGM and Final Dividend
Communication in respect of deduction of tax at source (TDS) on the amount of Dividend income from Procter & Gamble Health Limited ( the Company )
Appointment of Mr. Abhijit Roy as Sales Leader (South and East region) and Exports Leader of the company w.e.f. July 01, 2026.